Pliva Opens New Oral Solid Forms Facility

Oct 23, 2013

Pliva's new oral solid forms facility at its production site in Zagreb will increase Pliva's production capacities for tablets and capsules in addition to increasing exports as the majority of these products are intended for international markets. The $100 million investment also covers the transfer of the existing pilot plant for tablets to the new facility and an increase of production capacities for sterile forms.

This new facility will raise Pliva's and Teva's annual capacity by 2 billion tablets or more than 25%. Medicinal products manufactured in the new production facility are intended for EU and US markets, and commercial production will start as soon as the facility is approved by the FDA and other regulatory agencies.

Source: Pliva

lorem ipsum